You are here:
LinkedIn-button

News

Check here for our latest news

Intravacc Announces Favorable Preclinical Data for its Candidate Intranasal Gonorrhea Vaccine Avacc 11®

• Pre-clinical data of Avacc 11® demonstrated protection against gonorrhea infection • Global incidence rate of this sexual transmitted disease is at 87 million infections per year • OMV technology is a powerful tool to induce protective systemic and mucosal…

• Pre-clinical data of Avacc 11® demonstrated protection against gonorrhea infection • Global incidence rate of this sexual transmitted disease is at 87 million infections per year • OMV technology is a powerful tool to induce protective systemic and mucosal immunity • Data published in the peer reviewed journal MSphere of the American Society of Microbiology
Read more

Intravacc launches phase I clinical trial of Avacc 10®, an intranasal subunit booster vaccine for SARS-CoV-2

Intravacc launches phase I clinical trial of Avacc 10®, an intranasal subunit booster vaccine for SARS-CoV-2 Bilthoven, The Netherlands, 30 November 2022 –  Intravacc, a world leader in translational research and development of preventive and therapeutic vaccines, today announced that…

  • Randomized, double blinded, placebo-controlled trial
  • Evaluation of two doses in 36 volunteers
  • Mid-term data expected by end Q1 2023
Read more

Intravacc awarded US$14.6 Million NIH/NIAID contract to develop Intranasal Gonorrhea vaccine

Intravacc awarded US$14.6 Million NIH/NIAID contract to develop intranasal gonorrhea vaccine Bilthoven, The Netherlands, 5 October 2022 –  Intravacc, a world leader in translational research and development of preventive and therapeutic vaccines, today announced that it has been awarded a…

  • Gonorrhea is on the WHO high-priority list of antimicrobial resistant bacteria
  • World’s first intranasal prophylactic gonorrhea vaccine candidate
  • Mucosal vaccine platforms provides a broad opportunity for viral and bacterial vaccines
Read more

Intravacc announces additional favorable preclinical and toxicology data for Avacc 10®, an intranasal SARS-CoV-2 candidate vaccine

Intravacc announces additional favorable preclinical and toxicology data for Avacc 10®, an intranasal SARS-CoV-2 candidate vaccine Bilthoven, the Netherlands, 12 September 2022 – Intravacc, a world leader in translational research and development of preventive and therapeutic vaccines, today announced additional favorable…

  • Additional pre-clinical data of Avacc 10® indicate reduction in upper respiratory tract viral load and cross neutralization of variants of concern
  • Avacc 10® toxicology data support the start of a phase I clinical trial in Q4 2022
Read more

Intravacc and DZNE awarded EU funding to develop vaccine against genetic ALS variant

Intravacc and DZNE awarded EU funding to develop vaccine against genetic ALS variant Bilthoven, the Netherlands / Munich, Germany, 6 July 2022 – Intravacc, a world leading contract development and manufacturing organization (CDMO) of preventive and therapeutic vaccines and the…

  • Total amount of €2.5 million for amyotrophic lateral sclerosis (ALS) vaccine development
  • ALS vaccine is targeting the most common genetic ALS variant
  • 5-10% of all ALS cases are caused by a mutation in the C9orf72 gene
Read more
LinkedIn-button

NEED MORE INFORMATION?

Contact our
specialist

A team of 140+ specialists is at your disposal here in Bilthoven. Contact us to see how we can bring your vaccine concept ready for in-human trials.

CONTACT

Subscribe to our news update

Stay up to date with the latest developments, and be the first to receive our news updates and announcements.